Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of SAGE-718 in PD-MCI (PARADIGM)
NCT04476017Phase 2Completed
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Jul 2020
- Primary completion
- Mar 2022
- Modality
- Allosteric Modulators, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of dalzanemdor in mild cognitive impairment due to Parkinson's disease (PD-MCI), sponsored by Supernus Pharmaceuticals, Inc.. Started Jul 2020; status: completed.
02
Drugs
dalzanemdor
03
Conditions
mild cognitive impairment due to Parkinson's disease (PD-MCI)
Beyond the preview
Go deeper on NCT04476017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04476017.